

Printed as of 4/20/2024

# Disclosures

### Personal Commercial (9)

Self     Amgen   Consultant Fees/Honoraria   Modest (< \$5,000)   Prevention     Astra Zeneca   Research/Research Grants \$\$ HOPE-3   Significant (>= \$5,000)   Prevention     Bayer Healthcare Pharmaceuticals   Research/Research Grants \$\$ Consultant Fees/Honoraria   Significant (>= \$5,000)   Prevention     Bayer Healthcare Pharmaceuticals   Consultant Fees/Honoraria   Modest (< \$5,000)   Prevention     Novartis Canada   Consultant Fees/Honoraria   Modest (< \$5,000)   Heart Failure and Cardiomyopathie     Resvirologix   Data Safety Monitoring Board   Modest (< \$5,000)   Prevention     Sanofi-Aventis   Consultant Fees/Honoraria   Modest (< \$5,000)   Prevention	Company Name	Relationship Category	Compensation Level	Topic Area(s)
Astra Zeneca   Research/Research Grants   Significant (>= \$5,000)   Prevention     Bayer Healthcare Pharmaceuticals   Research/Research Grants   Significant (>= \$5,000)   Prevention     Bayer Healthcare Pharmaceuticals   Consultant Fees/Honoraria   Modest (< \$5,000)   Prevention     Novartis Canada   Consultant Fees/Honoraria   Modest (< \$5,000)   Prevention     Resvirologix   Data Safety Monitoring Board   Modest (< \$5,000)   Prevention	Self			
# HOPE-3   Significant (* ENTER)     Bayer Healthcare Pharmaceuticals   Research/Research Grants # COMPASS   Significant (>= \$5,000)     Bayer Healthcare Pharmaceuticals   Consultant Fees/Honoraria   Modest (< \$5,000)   Prevention     Novartis Canada   Consultant Fees/Honoraria   Modest (< \$5,000)   Heart Failure and Cardiomyopathie     Resvirologix   Data Safety Monitoring Board   Modest (< \$5,000)   Prevention	Amgen	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Laboration   # COMPASS   Evention     Bayer Healthcare Pharmaceuticals   Consultant Fees/Honoraria   Modest (< \$5,000)   Prevention     Novartis Canada   Consultant Fees/Honoraria   Modest (< \$5,000)   Heart Failure and Cardiomyopathie     Resvirologix   Data Safety Monitoring Board   Modest (< \$5,000)   Prevention	Astra Zeneca		Significant (>= \$5,000)	Prevention
Novartis Canada   Consultant Fees/Honoraria   Modest (< \$5,000)	Bayer Healthcare Pharmaceuticals		Significant (>= \$5,000)	
Resvirologix Data Safety Monitoring Board Modest (< \$5,000)	Bayer Healthcare Pharmaceuticals	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
	Novartis Canada	Consultant Fees/Honoraria	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
Sanofi-Aventis Consultant Fees/Honoraria Modest (< \$5,000) Prevention	Resvirologix	Data Safety Monitoring Board	Modest (< \$5,000)	Prevention
	Sanofi-Aventis	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
Servier Canada Consultant Fees/Honoraria Modest (< \$5,000)	Servier Canada	Consultant Fees/Honoraria	Modest (< \$5,000)	Prevention
The Medicines CompanyData Safety Monitoring BoardModest (< \$5,000)	The Medicines Company	Data Safety Monitoring Board	Modest (< \$5,000)	Prevention

# Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

## Personal Organizational or Other Non-Commercial (1)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Principal Investigator in clinical trial † Canadian Institutes of Health Research, Heart and Stroke Foundation of Canada	Research/Research Grants	None (\$0)	Prevention

### Clinical Trial Enroller (10)

Trial Name	Trial Sponsor	Trial Funding Source
FOURRIER	Amgen Inc.	
COMPASS	Bayer Healthcare Pharmaceuticals	
SODIUM-HF	Canadian Institutes of Health Research	
ACCELERATE	Eli Lilly and Company	
HARMONY	GSK	
DALGENE	Hoffman LaRoche	
GUIDE-IT	NHLBI	
TRANSITION	Novartis Corporation	
TIPS-3	Population Health Research Institute	Canadian Institutes of Health Research, Wellcome Trust, Heart and Stroke Foundation of Canada, Population Health Research Institute
APPRISE	Sanofi-Aventis	

### Institutional Financial Decision-Making Role (0)

No disclosures on record

#### **Expert Witness Testimony (0)**

No disclosures on record

#### Certified Education Attestation | Signed on 11/2/2016

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement

#### Confidentiality, Disclosure and Assignment Agreement | Signed on 11/2/2016

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

**Embargo** | Signed on 11/2/2016 URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 3/15/2017

#### **ACC and Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.